Literature DB >> 15191705

Erythropoietin (epoetin) as a protective factor for the brain.

Samit Malhotra1, Sheetal Nijhawan, Daniel M Rosenbaum.   

Abstract

Erythropoietin (EPO) has been viewed traditionally as a hematopoietic cytokine. Emerging evidence now exists supporting a physiologic role for EPO within the nervous system. EPO is expressed in the developing central nervous system and is capable of regulating the production of neuronal progenitor cells. There are numerous preclinical studies demonstrating a neuroprotective potential for EPO in a variety of disorders of both the central and peripheral nervous systems. A small pilot study in patients with acute ischemic stroke has recently been completed and the results are encouraging. Its mechanism of action is multifactorial but probably related to its ability to act as an antiapoptotic agent. Its widespread use clinically for the treatment of anemias has given us the experience and knowledge of its safety and pharmacokinetics. EPO is thus an ideal compound to study for the potential treatment of a variety of neurologic disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15191705     DOI: 10.1007/s11883-004-0062-1

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  60 in total

1.  Mechanisms of the potentiation by adenosine of adenosine triphosphate-induced calcium release in tracheal smooth-muscle cells.

Authors:  M C Michoud; F C Tao; A A Pradhan; J G Martin
Journal:  Am J Respir Cell Mol Biol       Date:  1999-07       Impact factor: 6.914

2.  In vivo evidence that erythropoietin has a neuroprotective effect during subarachnoid hemorrhage.

Authors:  M Buemi; G Grasso; F Corica; G Calapai; F M Salpietro; T Casuscelli; A Sfacteria; C Aloisi; C Alafaci; A Sturiale; N Frisina; F Tomasello
Journal:  Eur J Pharmacol       Date:  2000-03-24       Impact factor: 4.432

3.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

Review 4.  Current aspects of pathophysiology and cell dysfunction after severe head injury.

Authors:  J Sahuquillo; M A Poca; S Amoros
Journal:  Curr Pharm Des       Date:  2001-10       Impact factor: 3.116

5.  Human neuroglobin, a hexacoordinate hemoglobin that reversibly binds oxygen.

Authors:  J T Trent; R A Watts; M S Hargrove
Journal:  J Biol Chem       Date:  2001-06-27       Impact factor: 5.157

6.  Erythropoietin gene expression in human, monkey and murine brain.

Authors:  H H Marti; R H Wenger; L A Rivas; U Straumann; M Digicaylioglu; V Henn; Y Yonekawa; C Bauer; M Gassmann
Journal:  Eur J Neurosci       Date:  1996-04       Impact factor: 3.386

7.  Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression.

Authors:  Tong-Chun Wen; Yasutaka Sadamoto; Junya Tanaka; Peng-Xiang Zhu; Kimihiko Nakata; Yong-Jie Ma; Ryuji Hata; Masahiro Sakanaka
Journal:  J Neurosci Res       Date:  2002-03-15       Impact factor: 4.164

8.  Post-transcriptional regulation of erythropoietin mRNA stability by erythropoietin mRNA-binding protein.

Authors:  E C McGary; I J Rondon; B S Beckman
Journal:  J Biol Chem       Date:  1997-03-28       Impact factor: 5.157

9.  Permanent focal cerebral ischemia activates erythropoietin receptor in the neonatal rat brain.

Authors:  Tong-Chun Wen; Marta Rogido; Tom Genetta; Augusto Sola
Journal:  Neurosci Lett       Date:  2004-01-30       Impact factor: 3.046

10.  Erythropoietin prevents ischemia-reperfusion from inducing oxidative damage in fetal rat brain.

Authors:  Ihsan Solaroglu; Ayse Solaroglu; Erkan Kaptanoglu; Suat Dede; Ali Haberal; Etem Beskonakli; Kamer Kilinc
Journal:  Childs Nerv Syst       Date:  2002-12-14       Impact factor: 1.475

View more
  4 in total

1.  Effect of erythropoietin combined with hypothermia on serum tau protein levels and neurodevelopmental outcome in neonates with hypoxic-ischemic encephalopathy.

Authors:  Hong-Yan Lv; Su-Jing Wu; Qiu-Li Wang; Li-Hong Yang; Peng-Shun Ren; Bao-Jun Qiao; Zhi-Ying Wang; Jia-Hong Li; Xiu-Ling Gu; Lian-Xiang Li
Journal:  Neural Regen Res       Date:  2017-10       Impact factor: 5.135

Review 2.  Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer's Disease.

Authors:  José J Jarero-Basulto; Martha C Rivera-Cervantes; Deisy Gasca-Martínez; Francisco García-Sierra; Yadira Gasca-Martínez; Carlos Beas-Zárate
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-26

3.  The Relationship between Plasma Erythropoietin Levels and Symptoms of Attention Deficit Hyperactivity Disorder.

Authors:  Se-Hoon Shim; Yong-Ku Kim; Young Hwangbo; Hee-Jung Yoon; Ji Sun Kim; Youn Jung Lee; Young Sup Woo; Won-Myong Bahk
Journal:  Clin Psychopharmacol Neurosci       Date:  2021-05-31       Impact factor: 2.582

4.  Current and emerging treatments for amyotrophic lateral sclerosis.

Authors:  Stefano Zoccolella; Andrea Santamato; Paolo Lamberti
Journal:  Neuropsychiatr Dis Treat       Date:  2009-11-16       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.